{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune+device&page=2", "query": { "intervention": "Optune device", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune+device&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-07T01:16:04.556Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03194971", "title": "NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Tumor samples from patients treated with TTFields at initial diagnosis.", "type": "OTHER" }, { "name": "Tumor samples from patients treated with TTFields at tumor recurrence.", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-06-01", "completion_date": "2023-06-04", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194971" }, { "nct_id": "NCT03995667", "title": "Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma", "Limited Stage Lung Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tumor Treating Fields Therapy", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 3, "start_date": "2019-06-11", "completion_date": "2022-08-04", "has_results": true, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Portland, Oregon", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03995667" }, { "nct_id": "NCT03430791", "title": "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Nivolumab 240 mg IV", "type": "DRUG" }, { "name": "Nivolumab 3 mg/kg", "type": "DRUG" }, { "name": "Ipilimumab 1 mg/kg", "type": "DRUG" }, { "name": "NovoTTF200A (Optune)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-12-05", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03430791" }, { "nct_id": "NCT03223103", "title": "Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Poly-ICLC", "type": "DRUG" }, { "name": "Tumor Treating Fields", "type": "DEVICE" }, { "name": "Peptides", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "DEVICE", "BIOLOGICAL" ], "sponsor": "Adilia Hormigo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2018-03-01", "completion_date": "2029-05-12", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223103" }, { "nct_id": "NCT02663271", "title": "TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Glioblastoma", "Malignant Glioma", "GBM" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Optune", "type": "DEVICE" }, { "name": "Brain MRI", "type": "OTHER" }, { "name": "Quality of Life Questionnaires", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 10, "start_date": "2016-12-19", "completion_date": "2021-06-11", "has_results": true, "last_update_posted_date": "2022-06-23", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 2, "location_summary": "Gainesville, Florida • St Louis, Missouri", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663271" }, { "nct_id": "NCT06556563", "title": "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Optune® device", "type": "DEVICE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "NovoCure GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 741, "start_date": "2025-02-03", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06556563" }, { "nct_id": "NCT01892397", "title": "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Optune (NovoTTF-100A)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-06", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 9, "location_summary": "Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892397" }, { "nct_id": "NCT03705351", "title": "Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Cancer of Brain", "Glioblastoma Multiforme", "Brain Tumor" ], "interventions": [ { "name": "Tumor Treating Fields", "type": "DEVICE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DEVICE", "DRUG", "RADIATION" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 7, "start_date": "2019-12-02", "completion_date": "2022-02-24", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 2, "location_summary": "San Francisco, California • Portland, Oregon", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03705351" }, { "nct_id": "NCT03501134", "title": "Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "NovoTTF", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-08-08", "completion_date": "2021-06-03", "has_results": false, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501134" }, { "nct_id": "NCT02847559", "title": "Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic (Malignant) Meningioma", "Atypical Meningioma", "Grade II Meningioma", "Grade III Meningioma", "Recurrent Meningioma", "Supratentorial Meningioma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Electric Field Therapy", "type": "PROCEDURE" }, { "name": "NovoTTF-200A Device", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DEVICE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-08-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-07T01:16:04.556Z", "location_count": 8, "location_summary": "Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02847559" } ] }